Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Selumetinib plus dexamethasone in R/R ALL: a Phase I/II trial

Britta Vormoor • 10 Dec 2023
ASH 2023
Acute Lymphoblastic Leukemia Leukemia Dexamethasone Selumetinib

Britta Vormoor, MD, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, discusses a Phase I/II trial (NCT03705507) investigating selumetinib, a MEK1/2 inhibitor, combined with dexamethasone in the treatment of relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Despite initial safety concerns, successfully addressed through dose adjustments, 44% of participants achieved complete remission, underscoring the potential promise of this combination in the treatment of ALL. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Britta Vormoor

Challenges in treating patients with RAS-pathway activating mutations in ALL
0:42
Challenges in treating patients with RAS-pathway activating mutations in ALL
Britta Vormoor • 10 Dec 2023
The issue of short-lived treatment responses in heavily pretreated patients with ALL
0:48
The issue of short-lived treatment responses in heavily pretreated patients with ALL
Britta Vormoor • 10 Dec 2023

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals